 San Francisco Chronicle | Roche cancer drugs and currency drive sales growth Pharma Times The firm's top-selling drug was MabThera/Rituxan (rituximab), approved for non-Hodgkin's lymphoma and chronic lymphocytic leukaemia as well as rheumatoid arthritis, which contributed 1.68 billion francs, an increase of 11%. Herceptin (trastuzumab) for ... Strong first-nine months sales for Roche, boosted by cancer drugs |
